Cargando…

Complete resection after pembrolizumab treatment followed by salvage surgery in stage IVB endometrial cancer: A case report

INTRODUCTION: There is little evidence regarding the treatment of stage IVB endometrial cancer. Therefore, chemotherapy is more likely to be chosen as the initial and first-line treatment. Pembrolizumab is a new treatment choice for unresectable endometrial cancer after first-line chemotherapy failu...

Descripción completa

Detalles Bibliográficos
Autores principales: Taguchi, Tomomi, Ito, Kimihiko, Yamashita, Michiko, Egawa-Takata, Tomomi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118171/
https://www.ncbi.nlm.nih.gov/pubmed/35658296
http://dx.doi.org/10.1016/j.ijscr.2022.107125
_version_ 1784710456926011392
author Taguchi, Tomomi
Ito, Kimihiko
Yamashita, Michiko
Egawa-Takata, Tomomi
author_facet Taguchi, Tomomi
Ito, Kimihiko
Yamashita, Michiko
Egawa-Takata, Tomomi
author_sort Taguchi, Tomomi
collection PubMed
description INTRODUCTION: There is little evidence regarding the treatment of stage IVB endometrial cancer. Therefore, chemotherapy is more likely to be chosen as the initial and first-line treatment. Pembrolizumab is a new treatment choice for unresectable endometrial cancer after first-line chemotherapy failure. PRESENTATION OF CASE: Herein, we report the case of a 56-year-old patient diagnosed with stage IVB endometrial cancer. After eight cycles of first-line chemotherapy, computed tomography (CT) revealed relapse with re-enlargement of the para-aortic lymph nodes. Since the primary tumour had high microsatellite instability, we switched to pembrolizumab treatment. Pembrolizumab was effective but could not be continued due to adverse events after 10 cycles. Positron emission tomography-CT revealed active cancer in the uterus and para-aortic lymph nodes. DISCUSSION: Since pembrolizumab treatment had to be discontinued, we performed salvage surgery, which achieved complete tumour removal, and the patient has had no evidence of disease for 16 months. CONCLUSION: This is the first case of complete surgical resection after administering pembrolizumab as a second-line treatment for advanced endometrial cancer.
format Online
Article
Text
id pubmed-9118171
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-91181712022-05-20 Complete resection after pembrolizumab treatment followed by salvage surgery in stage IVB endometrial cancer: A case report Taguchi, Tomomi Ito, Kimihiko Yamashita, Michiko Egawa-Takata, Tomomi Int J Surg Case Rep Case Report INTRODUCTION: There is little evidence regarding the treatment of stage IVB endometrial cancer. Therefore, chemotherapy is more likely to be chosen as the initial and first-line treatment. Pembrolizumab is a new treatment choice for unresectable endometrial cancer after first-line chemotherapy failure. PRESENTATION OF CASE: Herein, we report the case of a 56-year-old patient diagnosed with stage IVB endometrial cancer. After eight cycles of first-line chemotherapy, computed tomography (CT) revealed relapse with re-enlargement of the para-aortic lymph nodes. Since the primary tumour had high microsatellite instability, we switched to pembrolizumab treatment. Pembrolizumab was effective but could not be continued due to adverse events after 10 cycles. Positron emission tomography-CT revealed active cancer in the uterus and para-aortic lymph nodes. DISCUSSION: Since pembrolizumab treatment had to be discontinued, we performed salvage surgery, which achieved complete tumour removal, and the patient has had no evidence of disease for 16 months. CONCLUSION: This is the first case of complete surgical resection after administering pembrolizumab as a second-line treatment for advanced endometrial cancer. Elsevier 2022-04-27 /pmc/articles/PMC9118171/ /pubmed/35658296 http://dx.doi.org/10.1016/j.ijscr.2022.107125 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Taguchi, Tomomi
Ito, Kimihiko
Yamashita, Michiko
Egawa-Takata, Tomomi
Complete resection after pembrolizumab treatment followed by salvage surgery in stage IVB endometrial cancer: A case report
title Complete resection after pembrolizumab treatment followed by salvage surgery in stage IVB endometrial cancer: A case report
title_full Complete resection after pembrolizumab treatment followed by salvage surgery in stage IVB endometrial cancer: A case report
title_fullStr Complete resection after pembrolizumab treatment followed by salvage surgery in stage IVB endometrial cancer: A case report
title_full_unstemmed Complete resection after pembrolizumab treatment followed by salvage surgery in stage IVB endometrial cancer: A case report
title_short Complete resection after pembrolizumab treatment followed by salvage surgery in stage IVB endometrial cancer: A case report
title_sort complete resection after pembrolizumab treatment followed by salvage surgery in stage ivb endometrial cancer: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118171/
https://www.ncbi.nlm.nih.gov/pubmed/35658296
http://dx.doi.org/10.1016/j.ijscr.2022.107125
work_keys_str_mv AT taguchitomomi completeresectionafterpembrolizumabtreatmentfollowedbysalvagesurgeryinstageivbendometrialcanceracasereport
AT itokimihiko completeresectionafterpembrolizumabtreatmentfollowedbysalvagesurgeryinstageivbendometrialcanceracasereport
AT yamashitamichiko completeresectionafterpembrolizumabtreatmentfollowedbysalvagesurgeryinstageivbendometrialcanceracasereport
AT egawatakatatomomi completeresectionafterpembrolizumabtreatmentfollowedbysalvagesurgeryinstageivbendometrialcanceracasereport